title: Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
abstract: In clinical trials with a range of doses of recombinant interferon-alpha 2a, we observed a 25% overall incidence of neutralizing antibody development. Careful data analysis did not reveal a relationship between antibody development and therapeutic response. Of 752 patients evaluable for antibody development and clinical response, 31% of the antibody-positive patients and 28% of the antibody-negative patients had therapeutic responses. Although the formation of anti-IFN antibodies seems to be associated with most IFN preparations, incidence and clinical significance have been difficult to determine for a number of reasons. Different assays with differing sensitivities for the detection of IFN antibodies have been utilized in different studies. Additionally, important clinical variables that affect antibody development have often not been carefully controlled or analyzed. The relationship between antibody development and multiple related factors, such as route of administration, dose regimen, cumulative dose, duration of treatment, and the underlying disease, requires clarification. Initial analyses suggest that the median time to antibody development may vary with the dose regime and cumulative dose, as well as the route of administration. Carefully designed prospective studies controlling for influential clinical variables and utilizing standardized assay techniques are required for a meaningful analysis of the antigenic potential of all therapeutic protein products.
authors.affiliation: Department of Clinical Research and Development, Hoffmann-La Roche, Inc., Nutley, NJ 07110.
authors.forename: L M
authors.initials: LM
authors.lastname: Itri
authors.forename: M I
authors.initials: MI
authors.lastname: Sherman
authors.forename: A V
authors.initials: AV
authors.lastname: Palleroni
authors.forename: L M
authors.initials: LM
authors.lastname: Evans
authors.forename: L L
authors.initials: LL
authors.lastname: Tran
authors.forename: M
authors.initials: M
authors.lastname: Campion
authors.forename: R
authors.initials: R
authors.lastname: Chizzonite
mesh_terms: D000906:Antibodies / Q000032:analysis / Q000276:immunology*; D000937:Antigen-Antibody Reactions; D002986:Clinical Trials as Topic; D006801:Humans; D007370:Interferon Type I / Q000276:immunology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology* / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy; D011994:Recombinant Proteins
chemical_list: D000906:Antibodies; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins